Photo from wikipedia
E.E.M.: Consulting fees from Adaptive Biotechnologies, Celgene, Takeda, Sanofi, Janssen; Research Funding to University of Texas MD Anderson from: Merck, Quest Diagnostics, Sanofi, JW Pharma. M.I.W.: consulting for Acerta Pharma,… Click to show full abstract
E.E.M.: Consulting fees from Adaptive Biotechnologies, Celgene, Takeda, Sanofi, Janssen; Research Funding to University of Texas MD Anderson from: Merck, Quest Diagnostics, Sanofi, JW Pharma. M.I.W.: consulting for Acerta Pharma, Janssen; Research Funding to UT MD Anderson from: Acerta Pharma, Asana Biosciences, BeiGene, Celgene, Janssen, Juno Therapeutics, Kite Pharma, Onyx, Pharmacyclics, Proteolix; Honoraria from Celgene, Dava Oncology, Janssen, Proteolix,; Membership on an entity's Board of Directors or advisory committees: Janssen. R.Z.O.: Consulting for Amgen, Bristol-Myers-Squibb, Celgene, GSK Biologicals, Ionis Pharmaceuticals, Janssen, Juno Therapeutics, Kite Pharma, Legend Biotech, Molecular Partners, Sanofi, Servier, Takeda; Research funding to UT MD Anderson from: BioTheryX. Other authors declare no potential conflict of interest.
Journal Title: American Journal of Hematology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!